key: cord-0788652-3czrlj3n
authors: Stevens, Laura J.; Pruijssers, Andrea J.; Lee, Hery W.; Gordon, Calvin J.; Tchesnokov, Egor P.; Gribble, Jennifer; George, Amelia S.; Hughes, Tia M.; Lu, Xiaotao; Li, Jiani; Perry, Jason K.; Porter, Danielle P.; Cihlar, Tomas; Sheahan, Timothy P.; Baric, Ralph S.; Götte, Matthias; Denison, Mark R.
title: Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir
date: 2022-01-29
journal: bioRxiv
DOI: 10.1101/2022.01.25.477724
sha: b316fcd6a65e44b04d5bcd3b81111898c0ab3db0
doc_id: 788652
cord_uid: 3czrlj3n

The nucleoside analog remdesivir (RDV) is an FDA-approved antiviral for the treatment of SARS- CoV-2 infections, and as such it is critical to understand potential genetic determinants and barriers to RDV resistance. In this study, SARS-CoV-2 was subjected to 13 passages in cell culture with increasing concentrations of GS-441524, the parent nucleoside of RDV. At passage 13 the RDV resistance of the lineages ranged from 2.7-to 10.4-fold increase in EC50. Sequence analysis of the three lineage populations identified non-synonymous mutations in the nonstructural protein 12 RNA-dependent RNA polymerase (nsp12-RdRp): V166A, N198S, S759A, V792I and C799F/R. Two of the three lineages encoded the S759A substitution at the RdRp Ser759-Asp-Asp active motif. In one lineage, the V792I substitution emerged first then combined with S759A. Introduction of the S759A and V792I substitutions at homologous nsp12 positions in viable isogenic clones of the betacoronavirus murine hepatitis virus (MHV) demonstrated their transferability across CoVs, up to 38-fold RDV resistance in combination, and a significant replication defect associated with their introduction. Biochemical analysis of SARS-CoV-2 RdRp encoding S759A demonstrated a ∼10- fold decreased preference for RDV-triphosphate (RDV-TP) as a substrate, while nsp12-V792I diminished the UTP concentration needed to overcome the template-dependent inhibition associated with RDV. The in vitro selected substitutions here identified were rare or not detected in the >6 million publicly available nsp12-RdRp consensus sequences in the absence of RDV selection. The results define genetic and biochemical pathways to RDV resistance and emphasize the need for additional studies to define the potential for emergence of these or other RDV resistance mutations in various clinical settings. One Sentence Summary SARS-CoV-2 develops in vitro resistance to remdesivir by distinct and complementary mutations and mechanisms in the viral polymerase

SARS-CoV-2 infections have caused more than 850,000 deaths in the United States and 35 over 5 million deaths worldwide (1, 2) . Remdesivir The use of therapeutic RDV has been shown to improve disease outcomes and reduce 49 viral loads in SARS-CoV-infected mice, in mice infected with chimeric SARS-CoV encoding the 50 SARS-CoV-2 RdRp, in SARS-CoV-2 infected mice co-treated with therapeutic antibodies, and in 51 infected rhesus macaques(4, 7, 14-16). Furthermore, RDV potently inhibits viral replication of 52 both human endemic CoVs and bat CoVs in primary human lung cell cultures(4, 6). A large 53 double-blinded, randomized, placebo-controlled trial of intravenous RDV in adult patients 54

hospitalized with COVID-19 demonstrated that RDV was superior to placebo in shortening time 55

to recovery(17, 18) and recent data suggests 50% increased survival rates if given early in 56 circulating clinical isolates we analyzed the consensus sequences of >6 million clinical isolates of 125 SARS-CoV-2 submitted to the GISAID Database(23) prior to January 4, 2021 (Table S2 ). In the 126 absence of RDV selection, the S759A mutation was identified in submitted consensus sequences, 127

including the Delta variant only in a single isolate while the other nsp12 mutations were detected 128 at a frequency less than 0.02%, and none of the nsp12 mutations were observed among >130,000 129

Omicron variant consensus sequences submitted as of this writing. A clear limitation of this 130 dataset is that the details of isolation and raw sequence data are not available. Consensus 131 sequences most likely represent nucleotides present at >50% and that any single nucleotide 132 polymorphisms present <50% in the population would not be represented in this analysis. For 133 example, we detected the S759A substitution at 0.64% in the expanded clinical WA-1 isolate 134 received from the CDC, which may have importance for its eventual selection. Similarly, in the 135 GS-441524 lineage 1 passage 13, C799F was present at 38%, a level that would not be reported in 136 consensus sequence. Despite this limitation, the analysis can allow us to conclude that in the 137 absence of RDV-selective pressure the in vitro identified nsp12 mutations were not present as 138 dominant variants or propagated in circulating SARS-CoV-2 including Delta and Omicron 139 variants. This supports our hypothesis that the identified nsp12 mutations likely were associated 140 with GS-441524 selective pressure, a hypothesis we next tested. 141 142 nsp12-S759A and -V792I are associated with in vitro RDV resistance 143

The S759A residue substitution was selected in GS-441524 lineages 1 and 3, which 144 demonstrated the most CPE and EC50 increase of GS-441524-passaged lineages. In both lineages, 145 the S759A substitution emerged as a dominant change in the population in combination with at 146 contribution of S759A and V792I to RDV resistance in the context of adapted infectious virus, we 148 plaque-picked (PP), expanded, and sequenced sub-lineages derived from GS-441524-passaged 149 lineage 3 (Table 1 , Data file S1). We isolated a sub-lineage containing V792I alone and another 150 sub-lineage containing S759A in combination with V792I. Importantly, in these two sub-lineages, 151 no other NS mutations were detected at >5% elsewhere in replicase genes (Data file S1). In RDV 152 sensitivity assays, the S759A/V792I-containing sub-lineage was indistinguishable from the GS-153 441524-passaged lineage 3 population at RDV concentrations up to 3.3μM, with a 7.3-fold 154 increase in EC50 over the DMSO-passaged control as compared to an 8-fold increase in EC50 for 155 the GS-441524 lineage 3 P13 population virus ( Fig.1 , Table S1 ). Thus, the S759A/V792I plaque-156 picked sub-lineage recapitulated resistance phenotype of the GS-441524 lineage 3 P13 157 population. In contrast, the V792I-containing sub-lineage displayed a low-level resistance 158 phenotype corresponding to a 2.6-fold increase in EC50 compared to the DMSO-passaged virus. To define viral genetic progression toward resistance, we quantified the relative frequency 166 of RDV resistance-associated nsp12 mutations in the GS-441524 lineages 1-3 at P6, P9, and P13 167 by RNA-seq ( Fig.2 A-C) and direct nanopore MinION sequencing of DNA amplicons spanning 168 nsp12 coding domain (Fig.2 D-F) . The data results between the two methods were consistent in 169 thereafter, while V166A, S759A, and C799F were less abundant at P6 but by P13 were 171 prominent. In lineage 2, only C799R was detected at any passage by RNA-seq or nanopore 172 amplicon sequencing. In lineage 3, V792I became dominant in the P9 population, while S759A 173 was detected at ~2.5% by nanopore amplicon sequencing at P6 and P9, but by P13 was >65%. In 174 both lineage 1 and 3, emergence of S759A correlated with an increase in EC50 (2.6-to-10.4-fold in 175 lineage 1; 1.7-to-8.0-fold in lineage 3). 176

To determine the frequency with which resistance-associated mutations were present 177 individually or in haplotypic linkages, we employed long-read nanopore (MinION) sequencing 178 across full-length nsp12 amplicons and developed the bioinformatics pipeline, MutALink, to 179 quantify the absolute abundance of each mutation alone and in combination with other mutations 180 that occurred at >15% frequency within by P13 (Fig. 2 G can easily accommodate the RDV-TP 1'-cyano group. Some variation in the sidechain 202 conformations of T687 and S759 was observed across the available cryo-EM structures and may 203 be dependent on the state of RNA and substrate binding. A computational assessment of these 204 conformations within the RDV-TP pre-incorporation model suggested that a state which oriented 205 the hydroxyls toward the RDV-TP 1'-cyano was optimal. The resulting hydrogen bonds were 206 weak (2.5 Å for T287 and 2.8 Å for S759), but this overall favorable interaction suggested a 207 potential advantage of RDV-TP over natural substrates. Modeling the S759A mutation showed a 208 loss of one of these hydrogen bonds, and from that we predicted decreased binding affinity of In all subsequent experiments we targeted S759A and V792I for genetic and biochemical 220 analysis, since: 1) they were associated with the most increase in measured resistance; 2) they 221 could be isolated alone (V792I) and together (S759A/V792I) in virus clones; and 3) S759A, 222 located in the nsp12-RdRp LS759DD active motif modeled a plausible change in interaction with 223 RNA. To directly test the capacity of S759A and V792I substitutions to mediate RDV resistance 224 in isogenic virus backgrounds devoid of other mutations, we engineered individual S-to-A and V-225 to-I changes at the aligned identical and structurally orthologous S755 and V788 residues in the 226 nsp12-RdRp of the Betacoronavirus murine hepatitis virus (MHV) (Fig. 4) We next sought to define the mechanisms of S759A and V792I resistance. For 252 biochemical analysis, we expressed and purified SARS-CoV-2 WT, S759A, or V792I RdRp 253 complexes consisting of nsp7, nsp8, and nsp12, using approaches previously described(8). A key 254 characteristic of RDV-TP as an inhibitor of WT SARS-CoV-2 is that it is incorporated with 255 higher efficiency than its natural ATP counterpart by the viral RdRp(8, 29). To determine if a 256 change in selective substrate usage could explain the effect of S759A and V792I, we determined 257 the efficiency of incorporation of ATP over RDV-TP by measuring Vmax/Km for single nucleotide 258

incorporation events under steady-state conditions (Fig. 5 , Table 2 ). ATP and RDV-TP 259 incorporation were monitored with a model primer/template using WT RdRp and the S759A and 260 enzyme was 0.38, indicating that RDV-TP was preferred over ATP (Table 2 ). In contrast, the 262 selectivity value for the S759A mutant was 4, demonstrating a preferred use of ATP over RDV-263 TP. This shift was driven primarily by a marked reduction in the use of RDV-TP as a substrate 264 increased. S759A and S759A/V792I are indistinguishable in this assay and the phenotype is 285 driven by S759A and the reduced usage of RDV-TP as a substrate. In contrast, the V792I 286 substitution alone did not demonstrate a significant effect on selective incorporation of RDV-TP, 287 delayed chain-termination, or overcoming delayed chain-termination (Table 2, Fig 5, Fig. S3) . 288

This result indicated that the contribution of V792I to RDV resistance is likely based on a 289 different mechanism. 290

We previously reported that the MHV-V553L RDV resistance mutation, when tested as 291 the homologous V557L substitution in a SARS-CoV-2 biochemical system, conferred low-level 292 RDV resistance by improving incorporation of UTP opposite the RDV-MP in the template and 293 thereby reducing template-dependent inhibition(12). To test a potential effect of V792I, S759A, 294 and S759A/V792I on template-dependent inhibition, we prepared WT template-A in which a 295 single AMP was embedded, and template-R in which a single RDV-MP was embedded (Fig. 6) . 296

All enzymes were equilibrated so that the same amount of product was present in the absence of 297 UTP (Fig. 6B , lane "0", product 10). The S759A mutant behaved almost identically to WT in this 298 reaction, while V792I alone or S759A/V792I together lowered the UTP concentration needed to 299 overcome template-dependent inhibition (Fig. 6C, F) . Thus, distinct and complementary 300 mechanisms of resistance were associated with S759A and V792I and the two residue 301 substitutions combined provided an advantage to RNA synthesis in the presence of RDV. 302 303

We here show that SARS-CoV-2 is capable of evolving reduced susceptibility to GS-305 441524/RDV via substitutions in the nsp12 RdRp at, or in close proximity to, the RdRP S759DD 306 with differing degrees of population resistance, with lineage 3 co-evolving S759A and V792I 308 substitutions that together in plaque isolates demonstrated the greatest extent of RDV resistance. Although RdRp mutations previously have been reported in MHV(5) and SARS-CoV-317 2(30, 31) associated with RDV resistance, this is the first report of an amino acid substitution in a 318

CoV nsp12-RdRp S759DD catalytic motif, and which mediates the largest magnitude of RDV 319 resistance observed to date. Notably, mutations are well known at the structurally equivalent HIV-320 1 reverse transcriptase (RT) YM184DD active motif that confer resistance to nucleoside 321 analogs(32). The HIV-1 RT YM184DD motif is relatively conserved among reverse transcriptase 322 enzymes and M184V or M184I within this region has a significant effect on RT catalytic activity 323 and may confer high-level resistance (>100-fold) to lamivudine (Epivir) and emtricitabine 324 (Emtriva)(31, 33, 34). In our study, replacing the conserved S759 in the S759DD motif of the 325

RdRp with an alanine resulted in decreased sensitivity to RDV, yet exerting diminished impact 326 compared to similar changes in the HIV-1 RT. Nevertheless, these data pinpoint S759A-the 327 product of a single nucleotide change and tolerated amino acid substitution in the RdRp-as a 328

likely key determinant of RDV resistance. Finally, it remains to be determined if our in vitro 329 example is potentially informative as the RT M184V/I substitutions first identified in vitro have 331

repeatedly been confirmed to be selected in vivo (35) . 332

The results of this study, along with our published biochemical and genetic studies, 333

suggest that there are multiple potential genetic pathways to SARS-CoV-2 RDV resistance. These 334 pathways may evolve both common and unique determinants within and across divergent CoVs. Further, it will be critical to test mutations that are selected in other proteins of the CoV replicase 351 complex (Data file S1), specifically in the nsp14 exonuclease, a key determinant of CoV high 352 5-Fluorouracil, as well as low-level native resistance to RDV in the MHV model (5, 38, 39) . in-house pipeline, MutALink. Analysis was directed by sequential custom Bash shell scripts that 516 direct each module of the pipeline. The first module performs basecalling and alignment. 517

Specifically, following sequencing, raw FAST5 files were basecalled and demultiplexed using 518 Guppy v5.0.11 (Oxford Nanopore Technologies). Pass FASTQ files were aligned to the SARS-519

CoV-2 genome (MT020881.1) for each sample using minimap2(50), and alignments were 520 processed and filtered for reads containing sequences across all of nsp12 using SAMtools(51). 521

Alignment statistics were generated using NanoStat. The second module of the MutALink pipeline 522 calls and quantifies variant allele frequencies for candidate variants using Nanopolish(52). The 523 last module, genotype quantification, filters different combinations of candidate variants and 524 generates outputs for each lineage using a custom batch script, variant-specific javascript files 525 (V166A.js, N198S.js, V792I.js, S759A.js, and C799F.js), and the samjdk package from jvarkit 526 (53) using a separate Bash shell script for each lineage. Read counts were corrected manually for 527 duplicate counting between combinations, and the frequency of each genotype in each sample 528 passage compared to total mapped reads was reported and visualized using the Python package, 529 seaborn(54). First ATP was positioned in the active site, as were two Mg ++ ions. The corresponding template 536 base at position +1 was modified from A to U. D618, D760 and D761 were optimized to 537 coordinate the metal ions, and a conformational search was done on key sidechains in the active 538 site, including K545, R553, R555, D623, S682, T687, N691, D759 and K798(55). These residues, 539 as well as metals, ATP, and primer/template nucleotides P-1, T-1 and T+1 were then 540 minimized(56). Once optimized, ATP was modified to RDV-TP and the structure was minimized reported (8, 9, 12) . Enzyme concentration was 150 nM for both single and multiple nucleotide 557 incorporation assays were used to determine the preference for the natural nucleotide over RDV-559 TP. The selectivity value was calculated as a ratio of the incorporation efficiencies of the natural 560 nucleotide over the nucleotide analog. The discrimination value was calculated as a ratio of 561 mutant to WT selectivity. The efficiency of nucleotide incorporation was determined by the ratio 562 of Michaelis-Menten constants Vmax over Km as previously reported (8, 9, 12) . highlighting the polar residues that interact with the 2'OH and the 1'CN. S759 is seen to be in 887 close contact with the 1'CN, forming a favorable interaction that is lost with the S759A mutation. incorporation; reported as a raw value of product fraction of the incorporated nucleotide. b Km is a 941

Michaelis-Menten parameter reflecting the concentration (µM) of the nucleotide substrate at 942 which the velocity of nucleotide incorporation is half of Vmax. c Selectivity of a viral RNA 943 polymerase for a nucleotide substrate analogue is calculated as the ratio of the Vmax/Km values for 944 NTP and NTP analogue, respectively; as such, it is a unitless value. d The discrimination index is 945 calculated as a ratio of selectivity of the mutant over wild type. e All reported values have been 946 calculated on the basis of a 9-data point experiment repeated the indicated number of times (n). 947 f Standard error associated with the fit. g Reference. 948

Therapeutic efficacy of the small 603 molecule GS-5734 against Ebola virus in rhesus monkeys

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic 608 coronaviruses

Coronavirus Susceptibility to the Antiviral Remdesivir 612 mBio

Broad spectrum antiviral remdesivir inhibits human 616 endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA 617 polymerase

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV 623

Expressing the SARS-CoV-2 RNA Polymerase in Mice

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from 626 severe acute respiratory syndrome coronavirus 2 with high potency

The antiviral compound 629 remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory 630 syndrome coronavirus

Remdesivir is a delayed 632 translocation inhibitor of SARS-CoV-2 replication

Mechanism of SARS-CoV-2 polymerase stalling by 635 remdesivir

Template-dependent inhibition of coronavirus RNA-dependent RNA 638 polymerase by remdesivir reveals a second mechanism of action

Inhibition of SARS-CoV

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus 647 macaque model of MERS-CoV infection

Comparative therapeutic efficacy of 651 remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

ACTT-1 Study Group Members, Remdesivir for the Treatment of 664

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With 671

Moderate COVID-19: A Randomized Clinical Trial

Gilead's Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in 673

Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-674

/6/gileads-veklury-remdesivir-associated-with-a-reduction-in-mortality-rate-in-676 hospitalized-patients-with-covid19-across-three-analyses-of-large-ret)

GS-US-540-9012 (PINETREE) Investigators, Early Remdesivir to Prevent 682 Progression to Severe Covid-19 in Outpatients

Emerging RNA-Dependent RNA Polymerase Mutation in a 687

Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 688 2019

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with

Viral 704 replication. Structural basis for RNA replication by the hepatitis C virus polymerase

Structural Insights into Mechanisms of Catalysis and Inhibition in Norwalk Virus 708

Structural basis for active site closure by the poliovirus RNA-710 dependent RNA polymerase

Motif D of viral RNA-dependent RNA polymerases determines 713 efficiency and fidelity of nucleotide addition

COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA 717

Emerging SARS-CoV-2 720 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

In 725 vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-726 2

The Lysine 65 Residue in HIV-1 Reverse Transcriptase 728

Function and in Nucleoside Analog Drug Resistance

YADD 730 Mutants of Human Immunodeficiency Virus Type 1 and Moloney Murine Leukemia Virus

Reverse Transcriptase Are Resistant to Lamivudine Triphosphate (3TCTP) In Vitro

The 734 M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C 736

Characterization of human immunodeficiency 739 viruses resistant to oxathiolane-cytosine nucleosides

Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of 750

GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in 751 the African Green Monkey Model of RSV

Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to 756

Proofreading-758 deficient coronaviruses adapt for increased fitness over long-term passage without reversion 759 of exoribonuclease-inactivating mutations

Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules 761 (NIH Guidelines

Research Involving Enhanced Potential Pandemic Pathogens

Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced 766

Potential Pandemic Pathogens

An orally bioavailable broad-spectrum antiviral 778 inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in 779 mice

791 variant exhibits efficient replication ex vivo and transmission in vivo

Infectious cDNA of Mouse Hepatitis Virus Strain A59

High Fidelity of Murine Hepatitis

Virus Replication Is Decreased in nsp14 Exoribonuclease Mutants

Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential 801

Minimap2: pairwise alignment for nucleotide sequences

Twelve years of SAMtools and BCFtools

A complete bacterial genome assembled de novo using 808 only nanopore sequencing data

JVarkit: java-based utilities for

seaborn: statistical data visualization

Schrödinger Release 2021-2: Prime

814 multiprotein complexes

Sensitivity of P9 lineages to RDV in A549-hACE2 cells 856 as determined by change in genome copy number. (B) Percent inhibition calculated from genome 857 copy number (A) and fold-change in EC50

C) Sensitivity of P13 lineages to RDV in A549-hACE2 cells as determined by change in 859

Replication kinetics of P13 861 drug-passaged viral lineages compared to vehicle-passaged lineage 1. (F) Sensitivity to RDV of 862 plaque-pick (PP) isolates from GS-441524-passaged lineage 3 and vehicle-passaged lineage 1 863 population viruses and input virus in A549-hACE2 cells as determined by change in genome copy 864 number. Plaque-picks (PP) from lineage 3 were isolated and expanded in presence of 1uM GS-865 441524. (G) Percent inhibition calculated from raw genome copy number (F) and fold-change

Variants were mapped according to their genomic position and frequency, expressed 877 as a percentage of the total reads mapped to that position

The 0 point in red indicates a 923 reaction where [α-32 P] GTP was the only NTP present to control for contaminating NTPs in the 924 template preparations. (C,D) Graphical representations of the fraction of RNA synthesis beyond 925 position 11 with respect to total RNA products formed. (C) Comparison of reactions using 926 template A and template R with WT RdRp and increasing concentrations of UTP

Comparisons of WT and mutant enzymes. Data corresponding to UTP = 33 and 100 µM were 928 excluded to focus on the differences in the lower concentration range

We thank Dr. Natalie Thornburg at the Centers for Disease Control and Prevention in Atlanta, 821 USA for providing the WA-1 SARS-CoV-2 used in this study. Finally, we thank VUMC and 822 UNC Environmental Health and Safety personnel and institutional biosafety committees for 823 reviewing and approving the work described herein. All RDV passage and forward genetic 824 selection studies with SARS-CoV-2 were completed before the October 2020 FDA EUA and 825 approval for remdesivir. 826Author Contributions 836